CYCC News and Press, Cyclacel Pharmaceuticals Inc. From 04/20/20

Gainers: Cyclacel Pharmaceuticals (NASDAQ: CYCC )  +91% . More news on: Cyclacel Pharmaceuticals, Inc., Benitec Biopharma Limited, VBI Vaccines Inc., Stocks on the move, , Read more ...

Cyclacel Pharmaceuticals (NASDAQ: CYCC ) has entered into an agreement with the University of Edinburgh to study fadraciclib (CYC065) and seliciclib (CYC202 or R-roscovitine), its clinical-stage CDK2/9 inhibitors, as early treatments for the inflammatory response observed in patients with ...

BERKELEY HEIGHTS, N.J. and DUNDEE, United Kingdom, April 20, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biopharmaceutical company developing innovative medicines today announced that it entered into an agreement with ...

BERKELEY HEIGHTS, N.J., April 14, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that ef...

Cyclacel Pharmaceuticals (NASDAQ: CYCC ) has registered for an equity offering . More news on: Cyclacel Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2019 Results Conference Call February 26, 2020 04:30 PM ET Company Participants Jan Medina - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance and Chief Operating Of...

Cyclacel Pharmaceuticals (NASDAQ: CYCC ): Q4 GAAP EPS of -$0.17 misses by $0.03 . More news on: Cyclacel Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

– Anticancer Activity of Fadraciclib (CYC065) Monotherapy in Patients with MCL1 Amplified Solid Tumor  and Fadraciclib -venetoclax Combination in Patients with Relapsed or Refractory AML/MDS and CLL – – Conference Call Scheduled February 26, 2...

BERKELEY HEIGHTS, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2019 fina...

The following slide deck was published by Cyclacel Pharmaceuticals, Inc. in conjunction with this Read more ...